Drug Approval | March 22, 2023
Zydus granted Orphan Drug Designation by USFDA for ZYIL1
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Various healthcare companies are already implementing high-tech solutions into existing healthcare systems.
Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
A funding to expand operations and provide better patient care
Chronic Kidney Disease is a growing epidemic with 850 million people affected worldwide.
Time to combine innovation, access and technology to deliver positive patient outcomes
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
The new powder flow tester can characterize powder flow properties, offering valuable insight for pharmaceutical processing and formulation
Smart-performance, fully biodegradable biopolymer sourced from renewable raw materials
Subscribe To Our Newsletter & Stay Updated
